Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis.

Next Previous
Trial Profile

A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daptomycin (Primary) ; Gentamicin
  • Indications Bacterial endocarditis; Staphylococcal infections
  • Focus Pharmacodynamics
  • Sponsors Cubist Pharmaceuticals

Most Recent Events

  • 22 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 15 Nov 2011 Planned end date changed from 1 Feb 2013 to 1 Nov 2011 as reported by ClinicalTrials.gov.
  • 15 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top